This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

INNATE PHARMA : Appoints Nicolai Wagtmann Chief Scientific Officer

  • Nicolai Wagtmann, previously Vice-President R&D at Novo Nordisk A/S, generated and developed a portfolio of therapeutic antibodies for the treatment of cancer and inflammatory diseases
  • François Romagné to lead CIMTECH and join Innate Pharma's Scientific Advisory Board

MARSEILLE, France, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announces the appointment of Nicolai Wagtmann as Chief Scientific Officer. His appointment to the Executive Board will be proposed at the next Supervisory board.

Nicolai Wagtmann joins Innate Pharma from Novo Nordisk A/S where he was Vice-President R&D and Head of Inflammation Biology. Nicolai Wagtmann is a pioneer of pharmacological approaches targeting innate immunity lymphocytes both in immuno-oncology and in inflammation. His research, initiated in academia, was developed in industry through the research collaboration between Innate Pharma and Novo Nordisk A/S.

Nicolai Wagtmann has resigned from Novo Nordisk A/S. His appointment as Innate Pharma's CSO is independent of Innate Pharma's corporate agreement with Novo Nordisk A/S and was supported unanimously by Innate Pharma's Supervisory board. He replaces François Romagné, co-founder of Innate Pharma, Chief Scientific Officer and member of the Executive Board since the Company's inception. From January 2014 François Romagné will lead CIMTECH, the new immuno-technology platform at Aix-Marseille University, which Innate Pharma co-founded. François Romagné will join Innate Pharma's Scientific Advisory Board at the same date.

Nicolai Wagtmann said: " My team at Novo Nordisk has enjoyed very productive interactions with Innate Pharma during a multi-year research collaboration which resulted in three first-in-class therapeutic antibodies undergoing clinical development. I have been impressed by Innate Pharma's unique scientific approach for therapeutically modulating the immune system. I now look forward to leading this excellent team to broaden and grow this unique platform and to advance several novel drug candidates into clinical development over the next few years. With the explosion of the immuno-pharmacoloy field, we have an exciting opportunity for building a high-value therapeutic antibody company".

François Romagné said: " The appointment of Nicolai is a great opportunity for Innate Pharma. Heading CIMTECH will allow me to focus on discovery and validation of new targets in immunology, in close link with fundamental research and of course Innate Pharma".

Hervé Brailly, CEO and co-founder of Innate Pharma, said: " We are very happy to welcome Nicolai, who brings not only a deep understanding of immunology and its creativity, but also an industrial vision which will be key for the growth and development of Innate Pharma's portfolio of drug candidates.

François was decisive in building the Company and its portfolio of first-in-class antibodies. The changes we are announcing today are an important step for Innate Pharma and also for the structuring and development of Marseille-Immunopole, confirming its world-class status as a collaborative ecosystem in immunology".  

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs